AgomAb Therapeutics Pitch Deck: All 21 Slides + Teardown

AgomAb Therapeutics' 21-slide deck is a highly technical, clinical-stage presentation that successfully secured $40.5M in Series B funding. The deck is structured around two core biological platforms: TGF-β targeting for Crohn’s disease and pulmonary fibrosis, and HGF targeting for organ failure. By utilizing clear pipeline charts (Slide 4) and detailed clinical trial designs (Slide 13), the company demonstrates a mature approach to drug development. The presentation avoids typical startup fluff, focusing instead on the biological 'Challenge' versus 'Our solution' (Slide 16) and the specific…

Key takeaways

• The deck clearly bifurcates the company's value into two distinct biological platforms: TGF-β and HGF (Slide 4).
• AgomAb identifies a specific high unmet need in Crohn’s disease, noting that 40-70% of patients require surgery within 10 years (Slide 10).
• The pipeline shows a lead candidate, AGMB-129, already progressing through Phase 1 trials (Slide 4).
• Clinical strategy is transparently mapped out, showing a hybrid Phase 1 study designed to drive Phase 2 success for AGMB-447 (Slide 13).
• The HGF platform addresses a specific biological hurdle: the very short 2-5 minute half-life of HGF (Slide 16).
• The company utilizes a 'partial agonist' strategy (AGMB-102) to trigger anti-fibrotic effects while avoiding unwanted proliferative signaling (Slide 19).
• The deck uses a 'Non-confidential' label, indicating it is designed for broad initial investor outreach rather than final due diligence (Slide 1).
• Visual communication of complex signaling pathways (Slide 16) helps bridge the gap between biological theory and therapeutic application.

Frequently asked questions

What is the primary therapeutic focus of AgomAb?

AgomAb focuses on growth factor-targeted therapeutics. Specifically, they develop drugs to repair damaged organs and treat fibrotic diseases. Their pipeline is split between a TGF-β targeting platform (focused on Crohn’s disease and Idiopathic Pulmonary Fibrosis) and an HGF-targeting platform (focused on organ failure and general fibrotic indications).

How far along is AgomAb’s clinical pipeline?

According to Slide 4, the lead program AGMB-129 (for Crohn’s disease) is in Phase 1. AGMB-447 (for IPF) and AGMB-101 (for organ failure) are in the IND-enabling stage, while AGMB-102 is currently in the discovery phase.

What specific problem does AgomAb solve in Crohn’s disease?

Slide 10 highlights that 50% of Crohn’s patients develop fibrostenotic strictures, and current therapies have no impact on the incidence or severity of these strictures. AgomAb’s AGMB-129 is a GI-restricted oral small molecule designed to address this specific unmet need.

What is the technical challenge associated with HGF targeting?

Slide 16 identifies two main challenges: HGF has a very short half-life of only 2-5 minutes, and it has a complex 3D structure that makes binding difficult. AgomAb’s solution involves MET receptor agonist monoclonal antibodies (mAbs) to utilize full MET biology.

Does the deck include financial projections or a specific funding ask?

No. The provided 21-slide deck focuses entirely on the science, clinical strategy, and market need. There is no mention of valuation, burn rate, or a specific dollar amount requested, which is common for 'non-confidential' biotech decks intended for initial screening.

AgomAb Therapeutics pitch deck: the facts

Company

AgomAb Therapeutics

Year

2023

Stage

Series B

Slides

21

Sector

Biotech

Deck type

Investor Pitch

Outcome

$40.5M Raised

Headquarters

Europe (Belgium)

AgomAb Therapeutics pitch deck PDF

The full AgomAb Therapeutics deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the AgomAb Therapeutics pitch deck was used for

This deck is a 21‑slide Series B investor presentation used by AgomAb Therapeutics in 2023 to support a $40.5M extension of its Series B round, bringing the total Series B financing to $114M.[1][2][4] The company develops growth factor–targeting therapeutics, leveraging two proprietary platforms against the TGF-β and HGF pathways to treat fibrotic diseases and organ failure, with lead programs AGMB‑129 for fibrostenotic Crohn’s disease and AGMB‑447 for idiopathic pulmonary fibrosis (IPF).[1][2][4] The extension round was led by Pfizer through its Pfizer Breakthrough Growth Initiative, with Walleye Capital and Asabys Partners participating alongside existing investors, and proceeds were primarily earmarked for advancing AGMB‑129 clinical trials and broader R&D pipeline development.[2][3][4][9][10][14][15]

Business model: AgomAb Therapeutics is a Belgian biotech company developing growth factor–targeting therapeutics to repair or regenerate damaged organs, with a focus on fibrotic diseases and organ failure via modulation of TGF-β and HGF signaling pathways.[1][2]

Round

Series B

Lead investor

Pfizer (Series B extension); Redmile Group (initial Series B close).

Investors

Pfizer (via Pfizer Breakthrough Growth Initiative), Redmile Group, Cormorant Capital / Cormorant Asset Management, Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology, V‑Bio Ventures

Headquarters

Belgium (AgomAb Therapeutics NV is described as a Belgian biotech company).[2][4]

Year: The initial Series B close occurred in 2021, and the $40.5M extension was announced in July 2022; coverage references this round and deck in 2022–2023.[1][2][3][4][9][10][14][15]

Raised: $114M total Series B financing, comprising a $74M initial close in March 2021 and a $40.5M extension announced July 2022.[1][2][3][4][9][10][14][15]

Industry: Biotechnology / Biopharmaceuticals (growth factor–targeting therapeutics for fibrotic diseases and organ failure).[1][2][4]

Total funding: AgomAb has raised at least $114M in Series B financing (including a $74M initial close in March 2021 and a $40.5M extension announced July 2022) and an additional $100M Series C round announced in October 2023, indicating total funding of at least $214M.[1][2][3][4][13][14][15]

Use of funds as presented: Proceeds were intended to advance clinical development of AgomAb’s pipeline, with a substantial portion directed to further trials of lead compound AGMB‑129 for fibrostenotic Crohn’s disease and broader research and development, including expansion of the company’s headcount.[2][3][4][9][15]

What happened after the AgomAb Therapeutics deck

The Series B deck under analysis supported AgomAb’s $40.5M Series B extension, which, together with the earlier $74M Series B, provided $114M to advance growth factor–targeting therapeutics like AGMB‑129 and AGMB‑447; this momentum contributed to the company’s ability to raise a subsequent $100M Series C round in 2023 for further clinical development.[1][2][3][4][9][10][13][14][15]

• Initial $74M Series B financing closed in March 2021 led by Redmile Group, with Cormorant and several existing investors
• Series B extension of $40.5M announced July 2022, led by Pfizer via the Pfizer Breakthrough Growth Initiative with Walle
• Series C financing of $100M announced October 2023 to further advance AGMB‑129 through Phase 2 trials in Crohn’s disease

What the AgomAb Therapeutics deck got right

• Strong, differentiated scientific platform narrative. The deck clearly positions AgomAb as a **leader in growth factor–targeting therapeutics** with a dual focus on TGF‑β and HGF pathways, which differentiates the company scientifically and frames a coherent platform across multiple fibrotic indications.[1][2]
• Multiple clinical‑stage assets with defined development status. It highlights a **broad clinical‑stage pipeline** with specific assets and statuses—AGMB‑129 in Phase 1 with Phase 1b in fibrostenotic Crohn’s disease planned, AGMB‑101 Phase 1‑ready, and AGMB‑447 in IND‑enabling studies—offering investors clear development progression rather than a single preclinical asset.[1]
• Compelling lead asset characterization and safety positioning. AGMB‑129 and AGMB‑447 are described with detailed pharmacology (GI‑restricted and lung‑restricted ALK‑5 inhibition, rapid metabolism/hydrolysis, clean safety panels, wide safety margins), which addresses core investor concerns around selectivity and safety in TGF‑β pathway modulation.[1]
• Strong unmet‑need framing in Crohn’s disease. The deck quantifies **unmet need in fibrostenotic Crohn’s disease** (stricture rates, surgery rates, recurrence, lack of impact from current therapies), effectively supporting the commercial and medical rationale for AGMB‑129.[1][10]
• Experienced, fully built leadership team highlighted. Slides present an **experienced R&D and corporate leadership team**, naming the CEO and C‑suite roles, which aligns with investors’ focus on execution capability in complex clinical programs.[1]
• Clear social proof via top‑tier investors and capital raised. The deck states that AgomAb has raised **$140M from top‑tier investors including Pfizer, Redmile, and Cormorant**, providing social proof and demonstrating prior validation from respected biotech investors.[1][2][3][4][9][14][15]

What could have been stronger

• Limited quantitative clinical and preclinical data shown in deck excerpts. The OCR text from the deck emphasizes the breadth of AgomAb’s pipeline and platforms but does not clearly present quantitative clinical data (e.g., specific efficacy endpoints, biomarkers, or comparative data versus standard of care) for AGMB‑129 or AGMB‑447, which can make it harder for investors to assess the strength of the evidence behind the “marked anti‑fibrotic and anti‑inflammatory efficacy” claims.[1]
• Investor and capitalization details only high‑level. While the deck notes that AgomAb has raised $140M from top‑tier investors including Pfizer, Redmile, and Cormorant, it does not (in the OCR excerpts) break down prior rounds, entry valuations, or ownership structure, which can be relevant for investors evaluating dilution and alignment.[1]
• Commercial strategy and market access appear under‑developed. The slides as captured via OCR focus heavily on scientific positioning and leadership bios but do not explicitly discuss commercial strategy (pricing, market access, competitive differentiation beyond “competition is still limited”), leaving revenue potential and go‑to‑market plans less developed in the deck sections visible.[1]
• Regulatory and development risk strategy not clearly detailed in excerpts. The deck’s framing of fibrostenotic Crohn’s disease and IPF highlights unmet need, but does not, in the text available, clearly articulate regulatory strategy (e.g., endpoints acceptable to regulators, accelerated pathways) or risk mitigation for long and complex trials in fibrotic indications.

How an investor would read this deck

What draws attention

• AgomAb’s focus on **growth factor–targeting therapeutics** via dual TGF‑β and HGF platforms for fibrotic diseases and organ failure positions it in a high‑need, mechanistically grounded area of biotech that can be attractive for investors seeking differentiated biology.[1][2][4]
• AGMB‑129 as a **GI‑restricted ALK‑5 inhibitor** for fibrostenotic Crohn’s disease directly addresses a serious unmet need where up to 50% of CD patients develop fibrostenotic strictures and surgery rates remain high, with limited competition.[1][10]
• AGMB‑447 as a **lung‑restricted ALK‑5 inhibitor** for IPF extends the platform into another high‑value fibrotic indication, supporting a pipeline story rather than a single‑asset bet.[1][4]
• The participation of leading investors (Pfizer via the Breakthrough Growth Initiative, Redmile Group, Cormorant, and others) and the total **$114M Series B** size provide external validation of AgomAb’s scientific and corporate strategy.[2][3][4][9][10][14][15]
• Series B proceeds are mainly directed toward advancing AGMB‑129 through clinical trials and supporting broader R&D, aligning capital deployment with clear development milestones that investors can track.[2][9][15]

Risks that stand out

• Clinical development risk is substantial: fibrostenotic Crohn’s disease and IPF are complex, heterogeneous conditions, and it remains uncertain whether ALK‑5 inhibition will translate into meaningful, durable clinical benefit without unacceptable safety issues.[2][3][9]
• Regulatory risk exists around defining appropriate endpoints and demonstrating disease modification in fibrotic indications, which can lead to longer, more expensive trials and potential delays.[2][3][4]
• Competitive risk is emerging, as unmet need in fibrostenotic Crohn’s disease and IPF has attracted increasing industry and key opinion leader interest, and future entrants could erode AgomAb’s first‑mover advantage.[1][10]
• Financing risk is non‑trivial: while AgomAb has secured $114M in Series B and later $100M in Series C funding, advancing multiple programs through mid‑ to late‑stage trials will likely require additional substantial capital raises.[1][2][3][4][13][14][15]

Questions this deck invites

• What specific clinical and biomarker endpoints are being used in AGMB‑129 trials for fibrostenotic Crohn’s disease, and what early data (safety and exploratory efficacy) have been observed relative to current standards of care?[2][3][9]
• How does AgomAb’s modulation of TGF‑β and HGF pathways compare to competing approaches in fibrotic diseases in terms of selectivity, safety, and potential for true disease modification?[1][2][4]
• What is the detailed IP position (patents, exclusivity windows) around AGMB‑129, AGMB‑447, and the broader growth factor platforms, including any freedom‑to‑operate assessments?[1][2][4]
• How is AgomAb planning to design and power Phase 2 and Phase 3 studies in fibrostenotic Crohn’s disease and IPF, given the challenges of patient selection, endpoints, and trial duration in fibrotic indications?[2][3][4][9]
• What are the company’s assumptions around peak sales, pricing, and reimbursement for AGMB‑129 and AGMB‑447 in the US and EU, and how do these map onto the current competitive and payer landscape in Crohn’s disease and IPF?

What founders can take from the AgomAb Therapeutics deck

• Highly specialized **mechanism‑of‑action narratives** (e.g., growth factor–targeting, ALK‑5 inhibition) can be made accessible to generalist investors when paired with clear statements of unmet need and simple positioning such as “true disease modification” in fibrotic diseases.[1][2]
• Connecting platform biology to **multiple high‑value indications** (fibrostenotic Crohn’s disease and IPF) reinforces that the round is backing a pipeline and platform rather than a single asset, which can strengthen the equity story.[1][2][4]
• Highlighting **trial readiness and specific timelines** (Ph1 completed or ongoing, Ph1b starting early 2023, Ph1 planned in H1’2023) gives investors near‑term milestones and potential news flow that can justify valuation and support follow‑on financings.[1]
• Explicitly naming **top‑tier investors and cumulative capital raised** (Pfizer, Redmile, Cormorant; $140M+ raised at the time) serves as powerful social proof and helps de‑risk perceptions of scientific and execution risk.[1][2][3][4][9][14][15]
• Framing indications through **compelling epidemiology and outcome data** (high rates of strictures, surgeries, and recurrence in Crohn’s disease; lack of impact from current therapies) effectively conveys urgency and opportunity without needing extensive financial projections on early‑stage slides.[
• A deck that clearly aligns **use of funds** with advancing a lead asset and strengthening the broader pipeline (as described for the Series B proceeds focused on AGMB‑129 and R&D expansion) helps investors see how capital translates into value inflection.[2][9][15]

AgomAb Therapeutics pitch deck: common questions

What does AgomAb Therapeutics do?

AgomAb Therapeutics is a Belgian biotech company developing growth factor–targeting therapeutics to repair or regenerate damaged organs, focusing on fibrotic diseases and organ failure by modulating TGF-β and HGF signaling pathways.[1][2][4] Its pipeline includes small molecules and antibodies aimed at achieving disease modification in indications such as fibrostenotic Crohn’s disease and idiopathic pulmonary fibrosis.[1][2][4]

Which fundraise was this AgomAb deck used for, and how much was raised?

The deck was used for AgomAb’s Series B extension financing announced in July 2022 and referenced in 2023 coverage, in which the company raised an additional $40.5M on top of a prior $74M Series B, bringing the total Series B round to $114M.[1][2][3][4][9][10][14][15] The presentation highlights AgomAb’s dual-platform strategy targeting TGF-β and HGF, its clinical-stage pipeline, and the use of proceeds to advance lead programs, particularly AGMB‑129 for fibrostenotic Crohn’s disease.[1][2]

Who invested in AgomAb Therapeutics’ Series B round and its extension?

According to AgomAb’s March 2021 announcement, the initial $74M Series B was led by Redmile Group, with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology, and V-Bio Ventures.[14][15] The July 2022 $40.5M Series B extension was led by Pfizer via its Pfizer Breakthrough Growth Initiative, with Walleye Capital and Asabys Partners joining alongside some of the existing backers.[2][3][4][9][10][12]

What are AgomAb’s lead drug candidates and target indications?

AgomAb’s lead candidate AGMB‑129 is an oral, potent, GI‑restricted small molecule inhibitor of ALK‑5, positioned for the treatment of fibrostenotic Crohn’s disease.[1][2][3][9] The deck also spotlights AGMB‑447, an inhaled, lung‑restricted ALK‑5 inhibitor for idiopathic pulmonary fibrosis, and earlier‑stage HGF pathway programs within its dual growth‑factor platform.[1]

Has AgomAb raised additional funding after this Series B deck?

AgomAb has a Series B deck used for the $40.5M extension bringing the round to $114M, which emphasizes its dual TGF‑β/HGF platforms, pipeline, and clinical development plans.[1][2] Subsequent financing included a $100M Series C round announced in October 2023, aimed at advancing its Crohn’s disease program through Phase 2; however, that later financing is associated with different materials and is distinct from the Series B pitch deck.[13]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• News & Events
• The Pitch Deck AgomAb Used to Raise a $114 Million ...
• Pfizer jumps into bed with Agomab, leading series B ...
• Agomab bags $114 million in thriving regenerative medicine sector
• Victor Kotsev
• Argenx news - the latest biotech news from Labiotech.eu
• AgomAb Therapeutics - DHbriefs
• AgomAb Therapeutics - Raised $238M Funding from 16 investors - Tracxn

AgomAb Therapeutics pitch deck slides

What each slide of the AgomAb Therapeutics pitch deck says

Slide 1

Leader in Growth Factor- Targeting Therapeutics Non-confidential deck July 2022 Vy) AGOMAB

Slide 2

@ Leader in growth factor-targeting therapeutics Growth factor focus Broad clinical-stage pipeline Build for success Modulate growth factor signalling pathways to achieve true disease modification Applying small molecules and antibodies to specific targets Two proprietary platforms targeting the TGF-B and HGF pathways AGMB-129 in Ph1; AGMB-101 Ph1-ready, and AGMB-447 in IND-enabling studies Therapeutic focus on acute and (severe) fibrotic diseases Additional research-stage programs to grow clinical pipeline further Experienced leadership team with proven R&D and corporate expertise $140M raised from top-tier investors including Pfizer, Bl, Redmile & Cormorant Rich clinical news flow driving…

Slide 3

Vy) Disease modification through growth factor modulating therapeutics mun cal Growth factor Modalities Assets nce nfpmmaron [rem ‘Myolibroblase = Transforming Growth = Organ-restricted = AGMB-129 esha. Factor Beta (TGF-B) small molecule inhibitors = AGMB-447 = Hepatocyte Growth = Full & partial = AGMB-101 ; 7 - Factor (HGF) agonistic antibodies = AGMB-102 Fibrosis Adupted from Li at , Frontiers in Pharmacology 2017 (P) Asomas NON-CONFIDENTIAL ®

Slide 4

Vy) Strong pipeline of growth factor targeted programs Indication Discovery IND-enabling Phase 1 Phase 1b/2 Phase 2b/3 — TGF-B TARGETING PLATO ——— Crohn's AGMB-129 disease Ghrestrcted oral small molecule ALS ohiiror I diopathic AGI\VIB-447 Lond Lung-restricted inhaled small molecule ALK-5 inhibitor I ——— HGF-TARGETING PLATO ——— oi [AGMBA0Z —————— failure AAGMB-101 is a full MET agonistic mAb Fibrotic AGMB-102 indications AGMB-102 is a partial MET agonistic mAb I==55 (P) Asomas NON-CONFIDENTIAL ®

Slide 5

@ Experienced R&D and corporate leadership team Tim Knotnerus Philippe Wiesel Paolo Michieli Torsten Dreier CEO cMo cso cpo Tolga Hassan Paul van der Horst Ellen Lefever Ramon Bosser CFO cBO GC Head of R&D Operations @ AGOMAB NON-CONFIDENTIAL Reginald Brys Head of Research Andrea Saez Head of Portfolio Mgmt ©)

Slide 6

Vy) Agomab’s growth strategy 2022 Series B extension =$40 Million 2021 fire Series B WALLEYE CAPITAL = £7) ORIGO asabys 2019 $74 Million NJ siopiARMA Series A - 2017 = $25 Million ‘se Founding Nhcement = $1 Million PORTIA Qe OMNES Adie anderd

Slide 9

a 4 @ AGMB-129: novel candidate for treatment of fibrostenotic CD m = Oral, potent and Gl-restricted small molecule inhibitor of ALK-5 Advantageous drug i ki Tissue restriction through rapid metabolization on first-pass in liver Clean profile for hERG, cardiac ion channels and kinase panels Marked anti-fibrotic and anti-inflammatory efficacy in vitro, in vivo and ex vivo Well-characterized profile Confirmed Gl-restricted PK profile in mouse, rat, dog and human Wide safety margins in GLP-tox studies = Ph1 SAD and food-interaction study finalized = Ph1 MAD ongoing = Ph1b in fibrostenotic Crohn's disease patients to start early 2023 Development status AGOMAB NON-CONFIDENTIAL @

Slide 10

@ High unmet need in fibrostenotic Crohn's Disease = 50% of all CD patients develop clinically apparent fibrostenotic strictures = As aresult, 40-70% needs surgery within 10 years after diagnosis due to strictures = Post-operative recurrence is common and recurrence by the third postoperative year is 85%-100% = Current therapies have no impact on stricture incidence and severity = High unmet need has led to increased industry and KOL interest, but competition is still limited ® QGOEVA(BS NON-CONFIDENTIAL

Slide 12

@ AGMB-447 is a novel candidate for the treatment of IPF a,fl = Inhaled, potent and lung-restricted small molecule inhibitor of ALK-5 Advantageous drug : = Tissue restriction through rapid hydrolyzation in the bloodstream properties = Clean profile for hERG, cardiac ion channels and kinase panels = Clear efficacy in therapeutic BLM mouse model and ex vivo experiments Well-characterized profile = Confirmed lung-restricted PK profile in mouse & rat = Wide safety margins in safety battery studies & non-GLP tox studies = GLP toxicology studies ongoing Development status = CMC upscaling & optimization ongoing = Ph1 in healthy volunteers planned for H1'2023 AGOMAB NON-CONFIDENTIAL @

Slide text above is read directly from the AgomAb Therapeutics deck PDF embedded on this page.

Related fundraising guides (24)

• Bloom Community Pitch Deck Teardown: Scaling Niche Social Networks Through Event Flywheels
• Haystack Oncology Pitch Deck Teardown: A Masterclass in Pedigree-Driven Biotech Fundraising
• airSlate Pitch Deck Teardown: A $51.5M Series C Masterclass in Growth and Product Consolidation
• Empion Pitch Deck Teardown: A Culture-First Approach to Automated Recruitment
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• Circles Pitch Deck Teardown: A $16.5M Series A Bet on Scalable Peer Support
• Impossible Kicks Pitch Deck Teardown: Scaling High-Volume Physical Retail for Sneaker Resale
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• CAMP4 Therapeutics Pitch Deck Teardown: A $100M Masterclass in Biotech Platform Validation
• Hintsa Pitch Deck Teardown: A $5.2M Masterclass in High-Performance Wellness Branding
• Anja Health Pitch Deck Teardown: A Narrative-Led Approach to Cord Blood Banking
• Factorial Pitch Deck Teardown: A Narrative-Driven Series C Strategy for HR Tech
• Limetree Pitch Deck Teardown: A Case Study in Early-Stage Family Media Preservation
• Code First Girls Pitch Deck Teardown: A Masterclass in B2B Social Impact Scaling
• Leonardo.ai Pitch Deck Teardown: A Product-First Showcase of Generative AI Traction
• BetterManager Pitch Deck Teardown: A $16M Series A Built on Traction and Google Pedigree
• Handly Pitch Deck Teardown: A B2B2C Play for the €5 Trillion Craft Services Market
• AgBiome Pitch Deck Teardown: A $116M Series D Masterclass in Platform Validation
• EcoVadis Pitch Deck Teardown: A Masterclass in Growth-Stage Market Dominance
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers

This deck's categories (1)

• Series A & Series B Pitch Deck Examples

Decks from the same year (1)

• 2023 pitch deck examples

Decks from the same region (1)

• European pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with A

Decks in the same category (12)

• MySQL 2003 Series B Pitch Deck Breakdown
• Oscar Health Pitch Deck Breakdown
• LinkedIn 2004 Pitch Deck Breakdown: How Networks Became the Next Big Thing
• DoggyHut Pitch Deck Breakdown: The Perfect Series A Deck For A Company That Does Not Exist
• Monzo Pitch Deck Breakdown: Building the Bank of the Future
• Pendo Series B Pitch Deck Breakdown
• Taster Pitch Deck Breakdown: Scaling Digital Restaurant Brands via a Licensing Model
• Zio Studios Pitch Deck Breakdown: A Transmedia Pivot from Services to IP
• Hadean Pitch Deck Breakdown: Proving Technical Scale Through Enterprise Case Studies
• Now Pitch Deck Breakdown: A $29M Series A Built on Municipal Bond Securitization
• Hangry Pitch Deck Breakdown: Scaling Multi-Brand Virtual Restaurants in Indonesia
• Seedtag Pitch Deck Breakdown: Leveraging the Post-Cookie Era with Contextual AI

More pitch deck teardowns (16)

• Ageras Pitch Deck Teardown: A Multi-Product Ecosystem for SME Financial Services
• Ageras Group Pitch Deck Breakdown: The Ecosystem Play for SME Financial Services
• Ageras Pitch Deck Teardown: A Masterclass in Ecosystem Expansion and M&A Strategy
• AgFunder Pitch Deck Breakdown: A Minimalist Approach to Agriculture Capital Markets
• AgileRL Pitch Deck Teardown: Leveraging Open-Source Traction for a $7.5M Seed Round
• Agile Wash Pitch Deck Breakdown: Four Real Slides In A 37-Page Template
• Agility Health Pitch Deck Teardown: A Roll-Up Strategy in the Physical Therapy Market
• Golazzo$ Pitch Deck Teardown: Leveraging World Cup Momentum for Social Betting Expansion
• Agora Pitch Deck Breakdown: A Social Commerce Play for the European Beauty Market
• Agreatculture Indonesia Pitch Deck Teardown: A Hyper-Local Pre-Seed Play for Digital Farming
• Agreatculture Pitch Deck Teardown: A Hyper-Local Indonesian AgTech Marketplace Play
• Sensilize Pitch Deck Teardown: Precision Agriculture and the Israeli Ag-Tech Ecosystem
• AgriNation Pitch Deck Teardown: A Technical IoT Concept for Community Agriculture
• AGS Pitch Deck Teardown: A Masterclass in Post-IPO Operational Transparency
• AGV Protocol Pitch Deck Teardown: Tokenizing Real-World Energy and Compute Assets
• AGV Protocol Pitch Deck Teardown: Tokenizing the Intersection of Energy and AI Compute

Recently published pitch deck teardowns (12)

• Cirrus Identity Pitch Deck Breakdown: A Masterclass in High-Signal, Low-Noise Traction
• Convelio Pitch Deck Breakdown: Digitizing the $1.6 Trillion High-Value Logistics Market
• Daylight Pitch Deck Breakdown: Scaling Enterprise Hyperautomation via Low-Code
• Edfa3fly Pitch Deck Breakdown: A Masterclass in Visual Traction and Market Specificity
• eino Pitch Deck Breakdown: Solving the $65 Billion Waste in Telecom Network Upgrades
• Gas Pos Pitch Deck Breakdown: A 7-Slide Masterclass in High-Signal Minimalism
• GlobeKeeper Pitch Deck Breakdown: Modernizing Law Enforcement Communication
• 4rented Pitch Deck Teardown: A Minimalist Look at a Pre-Product Rental Marketplace
• 1847 Holdings Pitch Deck Teardown: A Public Approach to Micro-Cap Private Equity
• 23andMe Pitch Deck Breakdown: Scaling a Consumer Flywheel into a Therapeutics Powerhouse
• 1Checkin Pitch Deck Teardown: Solving the Fragmentation of Airline Check-ins
• 99atoms Pitch Deck Teardown: A Workflow Solution for the Event Coordination Market

Fundraising library · Pitch deck examples · Investor directory · Founder database